ReviewClinical cancer research : an official journal of the American Association for Cancer Research2015
Using CellMiner 1.6 for Systems Pharmacology and Genomic Analysis of the NCI-60.
Review in Clinical cancer research : an official journal of the American Association for Cancer Research, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 68 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
68 citing papers in PubMed.
- SLC39A6 as a pan-cancer promising biomarker and actionable therapeutic target for CH5132799 sensitivity.BMC cancer · 2026Article
- Multi-omics analysis of kidney renal cell carcinoma in silico with preliminaryFrontiers in immunology · 2026Article
- E2-regulated transcriptome complexity revealed by long-read direct RNA sequencing: from isoform discovery to truncated proteins.RNA biology · 2025Article
- Pharmacogenomic Drug-Target Network Analysis Reveals Similarity Profiles Among FDA-Approved Cancer Drugs.Pharmaceutics · 2025Article
- Leveraging platinum-protein interactions to overcome chemoresistance.Nature communications · 2025Article
- Landscape of cancer associated EpCAM mutations: molecular modeling, predictive insights and impact on patient survival.BMC cancer · 2025Article
- Prognosis, immunological features and potential mechanisms of HKR1 in prostate cancer via single-cell and bulk RNA-sequencing.BMC cancer · 2025Article
- Neutrophil-induced pyroptosis promotes survival in patients with hepatoblastoma.Cancer immunology, immunotherapy : CII · 2025Article
- Integrated pan-cancer analysis revealed therapeutic targets in the ABC transporter protein family.PloS one · 2025Article
- Multi-omics analysis identifies UBA family as potential pan-cancer biomarkers for tumor prognosis and immune microenvironment infiltration.Frontiers in immunology · 2025Article
- Comprehensive evaluation of immunological attributes and immunotherapy responses of positive T cell function regulators in colorectal cancer.BMC gastroenterology · 2024Article
- HIF-2α-dependent TGFBI promotes ovarian cancer chemoresistance by activating PI3K/Akt pathway to inhibit apoptosis and facilitate DNA repair process.Scientific reports · 2024Article
- Identification and validation of a prognostic model based on immune-related genes in ovarian carcinoma.PeerJ · 2024Article
- A pan-cancer analysis of anti-proliferative protein family genes for therapeutic targets in cancer.Scientific reports · 2023Article
- Identification of TMEM178 as a Potential Prognostic Biomarker and Therapeutic Target for Breast Cancer.Iranian journal of public health · 2023Article
- Establishment of a novel indicator of pyroptosis regulated gene transcription level and its application in pan-cancer.Scientific reports · 2023Article
- Identification and characterization of topoisomerase III beta poisons.Proceedings of the National Academy of Sciences of the United States of America · 2023Article
- CellMinerCDB: NCATS Is a Web-Based Portal Integrating Public Cancer Cell Line Databases for Pharmacogenomic Explorations.Cancer research · 2023Article
- Gene S-phase kinase associated protein 2 is a novel prognostic marker in human neoplasms.BMC medical genomics · 2023Article
- LncRNA WAC-AS1 expression in human tumors correlates with immune infiltration and affects prognosis.Hereditas · 2023Article
8 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
The NCI-60 cancer cell line panel provides a premier model for data integration, and systems pharmacology being the largest publicly available database of anticancer drug activity, genomic, molecular, and phenotypic data. It comprises gene expression (25,722 transcripts), microRNAs (360 miRNAs), whole-genome DNA copy number (23,413 genes), whole-exome sequencing (variants for 16,568 genes), protein levels (94 genes), and cytotoxic activity (20,861 compounds). Included are 158 FDA-approved drugs and 79 that are in clinical trials. To improve data accessibility to bioinformaticists and non-bioinformaticists alike, we have developed the CellMiner web-based tools. Here, we describe the newest CellMiner version, including integration of novel databases and tools associated with whole-exome sequencing and protein expression, and review the tools. Included are (i) "Cell line signature" for DNA, RNA, protein, and drugs; (ii) "Cross correlations" for up to 150 input genes, microRNAs, and compounds in a single query; (iii) "Pattern comparison" to identify connections among drugs, gene expression, genomic variants, microRNA, and protein expressions; (iv) "Genetic variation versus drug visualization" to identify potential new drug:gene DNA variant relationships; and (v) "Genetic variant summation" designed to provide a synopsis of mutational burden on any pathway or gene group for up to 150 genes. Together, these tools allow users to flexibly query the NCI-60 data for potential relationships between genomic, molecular, and pharmacologic parameters in a manner specific to the user's area of expertise. Examples for both gain- (RAS) and loss-of-function (PTEN) alterations are provided.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.